The present two-phase study was designed to determine the optimum hypnotic dose of triazolam and to assess any evidence of acute tolerance. Subjective and objective data were used to assess hypnotic efficacy. In the dose-titration phase, the dose of triazolam was increased in 0·5 mg increments to the highest level tolerated by each individual patient. Maximum tolerable doses ranged between 0·5 and 3·0 mg; however, all subjects experienced maximum therapeutic effect at 1·5 mg triazolam. During the 4-night acute tolerance portion of the study no clear evidence of tolerance was found.
Get full access to this article
View all access options for this article.
References
1.
GreenblattDJShaderRJ (1974) Benzodiazepines in clinical practice. Raven Press, New York. p 242–261
2.
VeldkampWStrawRNMetzlerCMDemissianosHV (1974) Efficacy and residual effect evaluation of a new hypnotic, triazolam. Journal of Clinical Pharmacology14, 102
3.
VogelGThurmondAGibbonsPEdwardsKSloanKSextonK (1975) The effect of triazolam on the sleep of insomniacs. Psychopharmacologia (Berl.) 41, 65
4.
WangRIH (1974) Hypnotics: methods of development and evaluation. Spectrum Publications, New York. p 297–326
5.
WangRIHStockdaleSL (1973) Hypnotic efficacy of triazolam in comparison to Flurazepam and placebo. Journal of International Medical Research1, 600
